In silico, diosgenin and yamogenin displayed stronger binding abilities than protodioscin to estrogen receptor α (ERα), key in hormone-dependent and independent tumors in which the activation of ERα is linked to cancer progression [13]. Here, ESR1 is linked to cancer.